A Novel Therapeutic
We’re creating the first potential treatment for Demodex blepharitis
What is TP-03?
TP-03 is a novel therapeutic that may offer treatment, if approved, for millions of patients with Demodex blepharitis.
Potentially 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.
TP-03 can change that.
- Designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific GABA-Cl channels
- Completed four Phase 2 trials, all of which consistently met endpoints
- Well-tolerated with no significant adverse events leading to treatment discontinuation across the four trials
- Pivotal Phase 2b/3 trials underway, with the potential to be the first FDA-approved therapeutic and standard of care for the treatment of Demodex blepharitis
The active ingredient in TP-03 is lotilaner, a well characterized anti-parasitic agent that targets parasite-specific GABA-CI channels.
Clinical Summary
Mars Study
Presented by Roberto Gonzalez-Salinas, M.D., Ph.D. at ARVO 2020 Virtual Meeting.
Mars and Jupiter Studies
Presented by Paul Karpecki, OD, FAAO at AAOPT 2020 Virtual Meeting.
Io and Europa Studies
Presented by Roberto Gonzalez-Salinas, M.D., Ph.D. on October 6, 2020.
2021 Tarsus Pharmaceuticals, Inc. All rights reserved.
TARSUS and the associated logo are trademarks of Tarsus Pharmaceuticals, Inc.
Contact Tarsus
Please reach out to us using the form below.